Home
Finance & valuation

Finance & valuation

SVB’s collapse is a reminder of how far IP finance still has to travel

Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it

The Market Makers of 2022: top 20 revealed

Marconi's Kasim Alfalahi takes the top spot for Avanci's stellar showing in our countdown of the patent market’s most innovative and influential dealmakers and decision takers

Patent litigation finance skyrockets in past three years

We compiled data from Westfleet Advisors’ annual litigation funding reports to find patent finance shot up by nearly 50% since 2020 – to the benefit of rights holders

Latest content

Why patent litigators are now central to a wide range of commercial disputes

The Long Read: It’s no longer all about infringement, write Michelle Avery, Nicole McTernan and Drew Sills of Ocean Tomo. Instead, IP specialists are increasingly being called on in a diverse array of corporate lawsuits

01 December 2021

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin

The deal shows how privacy and silo barriers to the commercialisation of information are being overcome

29 November 2021

The IP story to engage the c-suite is there, but it takes bravery to tell it

Saturday Opinion: After a highly successful IPBC in Seattle earlier this week, it is clear that there has never been a better time to take the value creation gospel to the boardroom

20 November 2021

How Aon helps lenders and borrowers manage risk in IP-backed deals

Brian Hinman, chief commercial officer at Aon IP Solutions, tells IAM how the group facilitates IP-backed funding deals centred on high-quality assets

18 November 2021

IPBC Global ends with questions about IP in the boardroom at the top of the agenda

The final day of this year’s event in Seattle saw some of the market’s biggest names explain how to get the attention of the c-suite

17 November 2021

Semiconductors, FRAND, diversity and danger – Day Two of IPBC Global 2021

Highlights from the plenaries, breakouts and networking sessions as the world’s premier IP business event continues in Seattle

16 November 2021

IPBC Global kicks off at a time when private equity money is pouring into the IP market

Delegates talk big ticket investments and speculate on Kathi Vidal’s USPTO Director confirmation hearing in the Senate

15 November 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum

05 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Unlock unlimited access to all IAM content